Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report details a specific share repurchase transaction executed on November 25, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,353.5 pence per share; lowest price paid was 1,320.5 pence per share.
- Treasury Holdings (Settled): 525,162,927 shares (9.42% of total issued share capital).
- Treasury Holdings (Including Unsettled): 528,082,927 shares (10.46% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,047,970,374 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 750,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury to 10.46% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (525,162,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,047,970,374 shares in issue) for disclosure threshold assessments.
- Review the price range paid (1,320.5 to 1,353.5 pence) to assess the cost of capital relative to market prices on November 25, 2011.